Dae Gon Ha

Jack Allen

Philip Nadeau

Yanan Zhu

Huidong Wang

Luca Issi

Lut Ming Cheng

Brian Cheng

Cheng Li

Eric Schmidt

Gena Wang

Greg Harrison

Jay Olson

Jingming Chen

Joon Lee

Julien [on for Liisa Bayko]

Mary Kate Davis

Mehdi Goudarzi

Mia Bongiorno

Nicholas Econom

Samantha Semenkow

Steven Seedhouse

- **Editas Medicine** nominated **EDIT-401** as its lead in vivo development candidate, an experimental gene editing medicine targeting hyperlipidemia.  **[1650664_20250925LN83231:2]** 
- **EDIT-401** achieved approximately **90% mean LDL cholesterol reduction** with a single dose in non-human primate studies, significantly outperforming standard-of-care therapies.  **[1650664_20250925LN83231:2]** 
- The company expects to achieve human proof-of-concept data by the **end of 2026** and plans to submit an investigational new drug application by **mid-2026**.  **[1650664_20250925LN83231:2]** 
- As of **June 30, 2025**, Editas Medicine reported **$178.5 million in cash, cash equivalents, and marketable securities**, providing an operational runway into the **second quarter of 2027**.  **[1650664_20250925LN83231:3]**

Editas Medicine Nominates Lead Gene Editing Candidate EDIT-401 and Updates Financial Position

Editas Medicine (EDIT)